Kidney Scar Tissue (Fibrosis): Causes, Progression & Management

Renal fibrosis—scarring from excessive extracellular matrix deposition—is the final common pathway of progressive chronic kidney disease (CKD). It is irreversible; the goal is to slow or halt progression.

Common Causes

  • Diabetic nephropathy
  • Hypertensive nephrosclerosis
  • Glomerulonephritis (IgA, FSGS, lupus)
  • Obstructive uropathy
  • Recurrent pyelonephritis
  • Ischemia (vascular disease, contrast nephropathy)
  • Toxins (NSAIDs, lithium, aristolochic acid)
  • Genetic (Alport, ADPKD)

Pathophysiology

Injury → inflammation → fibroblast activation → myofibroblast transformation → collagen I/III, fibronectin deposition → capillary rarefaction → hypoxia → more fibrosis (vicious cycle). TGF-β is the master cytokine.

Clinical Consequences

  • Loss of nephrons → reduced GFR → CKD progression.
  • Impaired concentrating ability, acid-base handling, hormone production (EPO, vitamin D).
  • Increased cardiovascular risk.

Management to Slow Progression

  1. RAAS blockade: ACEi/ARB (cornerstone; reduce intraglomerular pressure, anti-fibrotic).
  2. SGLT2 inhibitors: Empagliflozin, dapagliflozin—reduce CKD progression, CV events (even in non-diabetics).
  3. Blood pressure control: <130/80 mmHg (KDIGO).
  4. Glycemic control: HbA1c ~7% individualized.
  5. Diet: Moderate protein (0.8 g/kg), low sodium (<2g), plant-based emphasis.
  6. Avoid nephrotoxins: NSAIDs, IV contrast (if possible), certain antibiotics.
  7. Treat complications: Anemia, mineral bone disease, acidosis.
  8. Advanced: Dialysis, transplant when GFR <15 or uremic symptoms.

Early detection (urine ACR, eGFR) and multidisciplinary care preserve function longest.

Kidney Disease - Related Articles